Common use of Revocation or amendment Clause in Contracts

Revocation or amendment. This patent policy is subject to revocation or amendment by the Corporation. In case of doubt as to the interpretation of this patent policy, a definitive interpretation will be provided by the President or ▇▇▇▇▇▇▇ after receiving the advice of the Committee on Cooperative Research, Patents, and Licensing. This patent policy is effective as to all inventions/discoveries made on or after February 23, 1998. Revised February, 1998 [**] [**] [**] [**] [**] Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 3 pages were omitted. [**] YALE UNIVERSITY, a corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut and located in New Haven, Connecticut (“YALE”), and KOLLTAN PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware, and with principal offices located at ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, New Haven, CT 06511 (“LICENSEE”), have entered into that certain Third Amended and Restated License Agreement, dated March 14, 2013, as amended and/or restated from time to time (the “Agreement”), an exclusive license to YALE’s receptor tyrosine kinases (RTKs) intellectual property, which agreement YALE internally designates as contract number [**]. As set forth herein, the parties now wish to amend the Agreement. This Amendment Number One to Third Amended and Restated License Agreement (“Amendment No. 1”), which YALE will internally designate as [**], shall be effective as of March 21, 2014 (“Effective Date”).

Revocation or amendment. This patent policy is subject to revocation or amendment by the Corporation. In case of doubt as to the interpretation of this patent policy, a definitive interpretation will be provided by the President or ▇▇▇▇▇▇▇ after receiving the advice of the Committee on Cooperative Research, Patents, and Licensing. This patent policy is effective as to all inventions/discoveries made on or after February 23, 1998. Revised February, 1998 Copyright @ 2011, Yale University Office of Cooperative Research, New Haven, Connective, USA. Email: ▇▇▇@▇▇▇▇.▇▇▇ | Telephone: (▇▇▇) ▇▇▇-▇▇▇▇ | Fax: (▇▇▇) ▇▇▇-▇▇▇▇ Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Appendix F KOLLTAN PATENTS (Shaded Rows = International (PCT) and Foreign Applications) ▇▇▇▇▇ Day Matter No. Kolltan Reference No. Serial No. Title Filing Date Status [**] [**] [**] [**] [**] Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 3 2 pages were omitted. [**] Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. AMENDMENT NUMBER ONE TO THIRD AMENDED AND RESTATED LICENSE AGREEMENT YALE UNIVERSITY, a corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut and located in New Haven, Connecticut (“YALE”), and KOLLTAN PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware, and with principal offices located at ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, New Haven, CT 06511 (“LICENSEE”), have entered into that certain Third Amended and Restated License Agreement, dated March 14, 2013, as amended and/or restated from time to time (the “Agreement”), an exclusive license to YALE’s receptor tyrosine kinases (RTKs) intellectual property, which agreement YALE internally designates as contract number [**]. As set forth herein, the parties now wish to amend the Agreement. This Amendment Number One to Third Amended and Restated License Agreement (“Amendment No. 1”), which YALE will internally designate as [**], shall be effective as of March 21, 2014 (“Effective Date”).

Revocation or amendment. This patent policy is subject to revocation or amendment by the Corporation. In case of doubt as to the interpretation of this patent policy, a definitive interpretation will be provided by the President or ▇▇▇▇▇▇▇ after receiving the advice of the Committee on Cooperative Research, Patents, and Licensing. This patent policy is effective as to all inventions/discoveries made on or after February 23, 1998. Revised February, 1998 [**] [**] [**] [**] [**] Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 3 2 pages were omitted. [**] YALE UNIVERSITY, a corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut and located in New Haven, Connecticut (“YALE”), and KOLLTAN PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware, and with principal offices located at ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, New Haven, CT 06511 (“LICENSEE”), have entered into that certain Third Amended and Restated License Agreement, dated March 14, 2013, as amended and/or restated from time to time (the “Agreement”), an exclusive license to YALE’s receptor tyrosine kinases (RTKs) intellectual property, which agreement YALE internally designates as contract number [**]. As set forth herein, the parties now wish to amend the Agreement. This Amendment Number One to Third Amended and Restated License Agreement (“Amendment No. 1”), which YALE will internally designate as [**], shall be effective as of March 21, 2014 (“Effective Date”).